Taxotere Could Get Boost From NICE Prostate Cancer Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K.’s National Institute for Health & Clinical Excellence recommends coverage of Sanofi-Aventis’ docetaxal for hormone-refractory metastatic prostate cancer.
You may also be interested in...
NICE Split Decision: Yes To Docetaxel, No To Paclitaxel For Early-Stage Breast Cancer
U.K. agency recommends use of Sanofi-Aventis’ Taxotere for early-stage breast cancer one month after prostate cancer nod.
NICE Split Decision: Yes To Docetaxel, No To Paclitaxel For Early-Stage Breast Cancer
U.K. agency recommends use of Sanofi-Aventis’ Taxotere for early-stage breast cancer one month after prostate cancer nod.
Xinlay Phase III Back-Up Trial Winding Down
Abbott expects to have data by year-end on which to base a regulatory strategy for the prostate cancer drug.